Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Substance Abuse, Substance Use Disorder (SUD)_Opioid, Alcohol, Tobacco, Etc.
Pear Therapeutics, Inc. (NASDAQ: PEAR)

Organization & Developments: Pear Therapeutics

Parents

*RESET-O
2017: Pear Therapeutics gets de novo FDA clearance for reSET, a digital therapeutic for substance abuse
2018: FDA clears Pear’s smartphone app therapy for opioid use disorder
2018: Sandoz and Pear Therapeutics announce launch of reSET® for
2019: Proteus_Digital health start-up once worth $1.5 billion is racing to keep lights on as investors flee_www.cnbc.com
2020: PBM RemedyOne will offer Pear Therapeutics reSET, reSET-O
2020: Pear Therapeutics acquires new VR therapeutics, licenses CBT, vocal biomarker tech with flurry of new deals
2020: Pear Therapeutics homes in on reimbursement coverage with $80M Series D
2020: Pear's reSET-O for opioid use disorder saves payers $2,150 per patient, real-world claims review finds
2020: Series D led by SoftBank Vision Fund 2, Forth Management, Pilot House, Sarissa Capital, Shanda Group, QUAD Investment Management, Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI
2021: DTx company Pear inks slew of deals to integrate more digital biomarkers and a digital pill into platform
2021: Pear Therapeutics won breakthrough status for a digital therapeutic, reSET-A, meant to treat alcohol use disorder
2022: Pear Therapeutics undergoes another round of layoffs, cutting 22% of staff
2023: Pear Therapeutics files for bankruptcy
2023: Pear, tight on cash, considers strategic alternatives